

**Table 7.6a**  
**Immunosuppression Use for Induction, 2000 to 2009**  
**Recipients with Pancreas After Kidney (PAK) Transplants**

|                                    | Year of Transplant |       |       |       |       |       |       |       |       |       |
|------------------------------------|--------------------|-------|-------|-------|-------|-------|-------|-------|-------|-------|
|                                    | 2000               | 2001  | 2002  | 2003  | 2004  | 2005  | 2006  | 2007  | 2008  | 2009  |
| <b>Transplants</b>                 | 305                | 305   | 375   | 344   | 420   | 343   | 293   | 261   | 213   | 198   |
| <b>With Immunosuppression Info</b> | 299                | 303   | 372   | 336   | 409   | 337   | 283   | 249   | 205   | 192   |
| <b>Induction Drugs</b>             |                    |       |       |       |       |       |       |       |       |       |
| ALG                                | 0.0%               | 0.0%  | 0.0%  | 0.0%  | 0.0%  | 0.0%  | 0.0%  | 0.0%  | 0.0%  | 0.0%  |
| Atgam/NRATG/NRATS                  | 1.7%               | 0.3%  | 2.4%  | 0.6%  | 1.5%  | 3.3%  | 0.0%  | 1.2%  | 1.0%  | 0.0%  |
| OKT3                               | 3.0%               | 0.7%  | 1.3%  | 0.9%  | 0.2%  | 0.0%  | 0.7%  | 0.4%  | 1.0%  | 1.0%  |
| Thymoglobulin                      | 37.1%              | 50.5% | 51.9% | 50.9% | 57.2% | 53.7% | 56.2% | 61.4% | 51.7% | 61.5% |
| Zenapax                            | 32.4%              | 33.3% | 25.3% | 9.5%  | 6.6%  | 6.8%  | 2.5%  | 2.0%  | 3.9%  | 3.1%  |
| Simulect                           | 17.1%              | 13.2% | 8.3%  | 8.0%  | 5.4%  | 2.7%  | 6.7%  | 4.0%  | 8.3%  | 7.8%  |
| Campath                            | 0.0%               | 0.0%  | 0.0%  | 13.4% | 19.1% | 18.4% | 13.4% | 12.0% | 15.1% | 11.5% |
| <b>No Induction Drugs Recorded</b> | 33.4%              | 25.1% | 27.2% | 25.9% | 20.3% | 22.0% | 21.9% | 20.5% | 20.5% | 17.2% |

Source: OPTN/SRTR Data as of October 1, 2010.

Notes:

Induction drugs include any reported antilymphocyte antibodies and antibodies directed against lymphocyte receptors.

Individual induction drug percentages will not necessarily add up to 100 percent, as patients may be prescribed more than one induction drug.